HC Wainwright Has Bearish Estimate for GALT FY2027 Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities researchers at HC Wainwright cut their FY2027 earnings estimates for Galectin Therapeutics in a report released on Friday, November 15th. HC Wainwright analyst E. Arce now expects that the company will earn $1.25 per share for the year, down from their previous forecast of $1.29. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2028 earnings at $3.39 EPS.

Separately, StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th.

Galectin Therapeutics Stock Up 0.7 %

NASDAQ GALT opened at $2.77 on Monday. The company has a 50-day simple moving average of $2.69 and a two-hundred day simple moving average of $2.61. Galectin Therapeutics has a 12-month low of $1.55 and a 12-month high of $4.27. The firm has a market cap of $172.52 million, a price-to-earnings ratio of -3.79 and a beta of 0.62.

Institutional Trading of Galectin Therapeutics

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Galectin Therapeutics by 2.0% during the first quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after purchasing an additional 38,037 shares during the period. Squarepoint Ops LLC raised its stake in Galectin Therapeutics by 75.4% in the second quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock worth $190,000 after buying an additional 36,139 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Galectin Therapeutics by 317.6% in the second quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after buying an additional 367,610 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Galectin Therapeutics in the second quarter worth about $146,000. Finally, Marshall Wace LLP bought a new position in Galectin Therapeutics in the second quarter worth about $43,000. 11.68% of the stock is currently owned by hedge funds and other institutional investors.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.